Please login to the form below
basal insulin
This page shows the latest basal insulin news and features for those working in and with pharma, biotech and healthcare.
Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
The human pancreas naturally supplies a low, continuous rate of insulin, known as basal or background insulin. ... Tidepool Loop’s algorithm technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate
Latest news
-
Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment
Currently, the basal insulin products with the longest duration are injected once daily. ... The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin
-
Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment
Currently, the basal insulin products with the longest duration are injected once daily. ... Insulin icodec is a novel once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection
-
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo
has compared it to Lantus (insulin glargine 100 units/mL), which lost its patent last year. ... The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its
-
Sanofi exits Zynquista alliance with Lexicon
The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes franchise following
-
Success for AZ, setback for Sanofi in type 1 diabetes
There is a broad array of insulin products on the market, including short-acting versions used after meals and long-acting (basal) insulins designed to give background control of blood glucose, ... The decision is a blow to Sanofi’s hopes of rebuilding
More from news
Approximately 0 fully matching, plus 90 partially matching documents found.
Latest Intelligence
-
Harnessing commercial innovation
products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. ... We needed to ensure that people were safe. Then we needed to ensure that our insulin was made available to people in Japan.
-
Going the distance
The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from
-
Interview: Pierre Chancel, Sanofi Diabetes
ORBIT (Observational Registry for Basal Insulin Treatment) is a study focused on type 2 diabetes in China and the result of Sanofi's partnership with the CDS and George Institute for ... The company sees particular potential for Lyxumia as a combination
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
